U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Drugs
  3. News & Events for Human Drugs
  4. OTC Monograph Drug User Fee Program (OMUFA): Understanding FY 2021 User Fees Webinar - 06/03/2021
  1. News & Events for Human Drugs

Public | Virtual

Event Title
OTC Monograph Drug User Fee Program (OMUFA): Understanding FY 2021 User Fees Webinar
June 3, 2021

Date:
June 3, 2021
Time:
1:00 PM - 2:00 PM ET

 

 

Download Slides

 

 

Register for Upcoming Training

ABOUT

FDA will provide an overview of the Over-The-Counter Monograph Drug User Fee Program (OMUFA) and describe the key elements of the program as it relates to OMUFA user fees.

TOPICS COVERED

  • Provide an overview of OMUFA as it relates to user fees
  • Discuss the registration process for over-the-counter monograph drug facilities
  • Describe the different fee types for OMUFA
  • Discuss fiscal year 2021 target revenue, fee rates, and timelines
  • Discuss the penalties associated with failure to pay OMUFA user fees
  • Provide an overview of the fee payment process
  • Discuss OMUFA refund eligibility

FDA SPEAKERS

CAPT Teresa Ramson, Pharm.D., MBA, RAC
Deputy Director, Division of User Fee Management (DUFM)
Office of Management (OM) | CDER | FDA

CAPT Matt Brancazio, Pharm.D., MBA, RAC
Branch Chief, Policy and Operations Branch
DUFM | OM | CDER | FDA

LCDR Tramara Dam, Pharm.D., GWCPM
Program Management Officer, Policy and Operations Branch
DUFM | OM | CDER | FDA

INTENDED AUDIENCE

  • Regulatory affairs professionals working on over-the-counter monograph drug products and/or non-prescription drugs or who submit over-the-counter monograph order requests
  • Industry partners following the FDA’s implementation of the Over-the-Counter Monograph Drug User Fee Program known as OMUFA
  • General public with an interest in over-the-counter monograph drug products and/or non-prescription drugs
  • Researchers testing over-the-counter monograph drug products and/or non-prescription drugs
  • Foreign regulators of over-the-counter monograph drug products and/or non-prescription drugs
  • Consultants focused on processing, manufacturing, developing of over-the-counter monograph drug products and/or non-prescription drugs
  • Clinical research coordinators
  • Healthcare professionals specializing in over-the-counter monograph drug products or non-prescription drugs
  • Importers of over-the-counter monograph drug products and/or non-prescription drugs
  • Supply chain of over-the-counter monograph drug products and/or non-prescription drugs

FDA RESOURCES

Back to Top